Brief: Royalty Pharma Raises 2023 Guidance Adjusted Cash Receipts Expected To Be $2.95 Bln To $3.00 Bln
08/11/2023 12:26
Nov 8 (Reuters) - Royalty Pharma PLC RPRX.O :
* ROYALTY PHARMA - RAISING 2023 GUIDANCE ADJUSTED CASH
RECEIPTS
EXPECTED TO BE $2,950 TO $3,000 MILLION
Source text for Eikon: ID:nGNX16hHnn
Further company coverage: RPRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Royalty Pharma
See all newsAnalysis: Revolution Medicines' Europe efforts signal solo launch ambitions for cancer drug
U.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple
Royalty Pharma falls after Novartis' cholesterol drug fails in study
Brief: Royalty Pharma Announces Update On Novartis’ Phase 3 Topline Results For Pelacarsen
Teva's immune disorder drug meets main goal in mid-stage trial (updated)